Navitoclax

那维妥拉

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameNavitoclax
Drug Alias NameNavitoclaxumRG-7423RG-7433ABT-263
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis stimulantsApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsSkin MelanomaSolid tumoursPrimary Myelofibrosis +[29
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[32
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active IndicationsSkin MelanomaSolid tumoursPrimary Myelofibrosis +[18
Inactive IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Small Cell +[11

Other Information

ATC CodeN/A